Evidence map›Paper›PMID 36125711›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2022

Human Hepatocyte Transduction with Adeno-Associated Virus Vector.

Zhenwei Song, Wenwei Shao, Liujiang Song, Xieolei Pei, Chengwen Li

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 62% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Zhenwei SongGene Therapy Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Wenwei ShaoAcademy of Medical Engineering and Translational Medicine, Tianjin University, Tianjin, China.
Liujiang SongGene Therapy Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Xieolei PeiGene Therapy Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Chengwen LiGene Therapy Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. chengwen_li@med.unc.edu.
University of North Carolina at Chapel Hill · USTianjin Medical University · CN

Funding

Novel strategy to block Nabs for AAV gene deliveryR01AI168242 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Chengwen Li, Timothy Charles Nichols · 2022 to 2026
$3.0M
NIAID NIH HHS R01 AI168242
6 · The paper itself

Abstract

As the adeno-associated virus (AAV) vectors hold unique advantages over other viral vectors, AAV gene therapy has accumulated rapid progress and development. Liver-targeted gene therapy by AAV vectors has been successfully applied in clinical trials for many diseases. Low transduction efficiency and high prevalence of neutralizing antibodies (Nabs), however, are the major obstacles to further translate this therapeutic strategy into clinical trials. Pre-clinical evaluation on hepatocytes could help to elucidate the tropism of AAV serotypes for liver-targeted gene therapy, and could also provide a test model to develop novel AAV mutants with Nabs evasion and high liver tropism. Here, we described the basic laboratory procedure to apply the AAV vector to transduce human hepatocytes in vitro and in vivo with some tips gained from our own experience.

Indexed as

DependovirusGenetic VectorsAntibodies, NeutralizingGenetic TherapyHepatocytesHumansAntibodies, NeutralizingAdeno-associated virus vector (AAV)Liver chimeric micePrimary human hepatocyte (PHH)Transduction

Identifiers

PMID36125711
PMCPMC12817257
OpenAlexW4296501976

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.